University of Texas's MD Anderson Cancer Center: Neoadjuvant Immunotherapy Improves Outlook in High-Risk Melanoma
September 12, 2022
September 12, 2022
HOUSTON, Texas, Sept. 12 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma
* * *
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significa . . .
* * *
Starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma
* * *
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significa . . .